Methylprednisolone hemisuccinate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Methylprednisolone hemisuccinate is a water soluble corticosteroid used to treat severe allergic reactions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematological disorders, neoplastic diseases, nervous system conditions, ophthalmic diseases, renal diseases, respiratory diseases, and rheumatic disorders.

Brand Names
Solu-medrol
Generic Name
Methylprednisolone hemisuccinate
DrugBank Accession Number
DB14644
Background

A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 474.55
Monoisotopic: 474.225368055
Chemical Formula
C26H34O8
Synonyms
  • Methylprednisolone hemisuccinate
  • Methylprednisolone hydrogen succinate
  • Methylprednisolone succinate

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Symptomatic treatment ofAcute gouty arthritis•••••••••••••••••••••• ••••••• ••• ••••••••
Treatment ofAnkylosing spondylitis (as)•••••••••••••••••••••• ••••••• ••• ••••••••
Treatment ofBerylliosis•••••••••••••••••••••• ••••••• ••• ••••••••
Management ofCongenital adrenal hyperplasia (cah)•••••••••••••••••••••• ••••••• ••• ••••••••
Treatment ofCongenital hypoplastic anemia•••••••••••••••••••••• ••••••• ••• ••••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Methylprednisolone sodium succinate (the sodium salt of methylprednisolone hemisuccinate) has the same metabolic and anti-inflammatory actions as methylprednisolone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity.

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Acarbose.
AceclofenacThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone hemisuccinate is combined with Aceclofenac.
AcemetacinThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone hemisuccinate is combined with Acemetacin.
AcenocoumarolMethylprednisolone hemisuccinate may increase the anticoagulant activities of Acenocoumarol.
AcetohexamideThe risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Acetohexamide.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Methylprednisolone sodium succinateLEC9GKY20K2375-03-3FQISKWAFAHGMGT-SGJOWKDISA-M
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Methylprednisolone Sodium Succinate for InjectionPowder, for solution500 mg / vialIntramuscular; IntravenousTeva Italia S.R.L.2000-03-01Not applicableCanada flag
Methylprednisolone Sodium Succinate for InjectionPowder, for solution125 mg / vialIntramuscular; IntravenousTeva Italia S.R.L.2000-03-01Not applicableCanada flag
Methylprednisolone Sodium Succinate for InjectionPowder, for solution40 mg / vialIntramuscular; IntravenousTeva Italia S.R.L.2000-03-01Not applicableCanada flag
Methylprednisolone Sodium Succinate for InjectionPowder, for solution1 g / vialIntramuscular; IntravenousTeva Italia S.R.L.2000-03-01Not applicableCanada flag
Methylprednisolone Sodium Succinate for InjectionPowder, for solution5 g / vialIntramuscular; IntravenousTeva Italia S.R.L.Not applicableNot applicableCanada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
A-methapredInjection, powder, for solution40 mg/1mLIntramuscular; IntravenousHospira, Inc.2009-07-142013-05-01US flag
A-methapredInjection, powder, lyophilized, for solution40 mg/1mLIntramuscular; IntravenousHospira, Inc.2006-10-062010-07-01US flag
A-methapredInjection, powder, for solution125 mg/2mLIntramuscular; IntravenousHospira, Inc.2009-06-222013-05-01US flag
A-methapredInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousHospira, Inc.2006-10-062010-07-01US flag
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousTianjin Kingyork Pharmaceuticals Co., Ltd2021-04-20Not applicableUS flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
5GMR90S4KN
CAS number
2921-57-5
InChI Key
IMBXEJJVJRTNOW-XYMSELFBSA-N
InChI
InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1
IUPAC Name
4-{2-[(1R,3aS,3bS,5S,9aR,9bS,10S,11aS)-1,10-dihydroxy-5,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid
SMILES
[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C

References

General References
  1. FDA Approved Drug Products: Solu-Medrol (methylprednisolone sodium succinate) for injection [Link]
ChemSpider
16034
ChEBI
135765
ChEMBL
CHEMBL1201265
ZINC
ZINC000003977781
Wikipedia
Methylprednisolone

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
Not AvailableCompletedNot AvailableKidney Transplant Patients1somestatusstop reasonjust information to hide
Not AvailableCompletedOtherAdministration, Intravenous / Healthy Volunteers (HV) / Intranasal Administration / Methylprednisone Administration1somestatusstop reasonjust information to hide
Not AvailableCompletedPreventionSystemic Inflammatory Response Syndrome (SIRS) / Valvular Heart Diseases1somestatusstop reasonjust information to hide
Not AvailableCompletedTreatmentAbdominal Aortic Aneurysm (AAA)1somestatusstop reasonjust information to hide
Not AvailableCompletedTreatmentAortic Stenosis1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for solutionIntramuscular; Intravenous125 mg/2mL
SolutionIntravenous165.740 mg
Injection, powder, lyophilized, for solutionIntravenous500 mg
Injection, solutionIntramuscular; Intravenous250 mg
SolutionParenteral165.74 mg
InjectionIntramuscular; Intravenous
Injection, solutionIntramuscular; Intravenous1000 mg
Injection, powder, for solutionParenteral16 mg
Injection, powder, for solutionParenteral32 mg
InjectionIntramuscular; Intravenous1 g/16mL
InjectionIntramuscular; Intravenous125 mg/2mL
InjectionIntramuscular; Intravenous40 mg/1mL
InjectionIntramuscular; Intravenous500 mg/8mL
Injection, powder, for solution171 mg/2ml
Injection, powder, for solutionIntramuscular; Intravenous1 g/1
Injection, powder, for solutionIntramuscular; Intravenous125 mg/1
Injection, powder, for solutionIntramuscular; Intravenous125 mg
Injection, powder, for solutionIntramuscular; Intravenous40 mg/1
Injection, powder, for solutionIntramuscular; Intravenous500 mg
Injection, powder, for solutionIntramuscular; Intravenous500 mg/1
Injection, powder, for solution; injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg
Injection, powder, lyophilized, for solution684 mg
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous1 g/16mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous1 g/8mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/2mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous2 g/30.6mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous2 g/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous40 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous40 mg/1mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/8mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/4mL
Powder, for solutionIntramuscular; Intravenous1 g / vial
Powder, for solutionIntramuscular; Intravenous125 mg / vial
Powder, for solutionIntramuscular; Intravenous40 mg / vial
Powder, for solutionIntramuscular; Intravenous5 g / vial
Powder, for solutionIntramuscular; Intravenous500 mg / vial
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous20 mg
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous250 mg
InjectionIntramuscular; Intravenous250 mg
InjectionIntramuscular; Intravenous40 mg
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg
Injection, solutionIntramuscular; Intravenous125 mg
Injection, solutionIntramuscular; Intravenous15.78 mg
Injection, powder, for solution125 mg
InjectionIntramuscular; Intravenous20 mg
Injection, powder, for solution
Tablet
Solution500.000 mg
Injection, powder, for solutionParenteral1000 mg
PowderIntramuscular; Intravenous1000 mg/1vial
Injection, powder, for solutionParenteral500 mg
Injection, powder, for solution125 mg/2ml
Injection, powder, for solution500 mg
Injection, powder, for solutionIntramuscular; Intravenous1000 MG/16ML
Injection, powder, for solutionIntramuscular; Intravenous2000 MG/32ML
Injection, powder, for solutionIntramuscular; Intravenous40 MG/ML
Injection, powder, for solutionIntracavernous; Intramuscular40 mg/1
Injection, powder, for solutionIntramuscular; Intravenous1 g/1mL
Injection, powder, for solutionIntramuscular; Intravenous1 g/8mL
Injection, powder, for solutionIntramuscular; Intravenous125 mg/1mL
Injection, powder, for solutionIntramuscular; Intravenous2 g/30.6mL
Injection, powder, for solutionIntramuscular; Intravenous40 mg/1mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/1mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/4mL
Injection, powder, for solutionIntravenous1 g/1
Injection, powder, for solution; kitIntramuscular; Intravenous2 g/30.6mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/1mL
Kit; powderIntramuscular; Intravenous1 g / vial
Kit; powderIntramuscular; Intravenous125 mg / vial
Kit; powderIntramuscular; Intravenous40 mg / vial
Kit; powderIntramuscular; Intravenous500 mg / vial
Kit; powder, for solutionIntramuscular; Intravenous1 g / vial
Kit; powder, for solutionIntramuscular; Intravenous125 mg / vial
Kit; powder, for solutionIntramuscular; Intravenous40 mg / vial
Kit; powder, for solutionIntramuscular; Intravenous500 mg / vial
Powder, for solutionIntravenous125 mg/1mL
PowderIntramuscular; Intravenous125 mg/1vial
PowderIntramuscular; Intravenous40 mg/1vial
PowderIntramuscular; Intravenous500 mg/1vial
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous40 mg
Injection, powder, for solutionIntramuscular; Intravenous500 mg/8ml
PowderIntramuscular; Intravenous1000 MG
PowderIntramuscular; Intravenous500 MG
Powder, for solutionIntramuscular; Intravenous; Rectal125 mg / vial
Powder, for solutionIntramuscular; Intravenous; Rectal40 mg / vial
Injection, powder, for solutionIntramuscular; Intravenous20 mg
Injection, powder, for solutionIntramuscular; Intravenous250 mg
Injection, powder, for solutionIntramuscular; Intravenous40 mg
Injection, powder, for solutionIntramuscular; Intravenous
InjectionParenteral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0264 mg/mLALOGPS
logP2.43ALOGPS
logP1.83Chemaxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.66Chemaxon
pKa (Strongest Basic)-2.9Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area138.2 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity123.09 m3·mol-1Chemaxon
Polarizability49.87 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-052r-0004900000-c2cd56187e228f386ceb
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-052f-0009200000-755bd4b2c1e0d8817b2e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-052r-4338900000-db8155cb7658af04a306
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0076-2009000000-a83c708fc156222b0abb
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0571-4689300000-bbdbeaec99edf0f90ce5
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00fr-8009100000-519aed3487b0275075d8
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-226.0317817
predicted
DarkChem Lite v0.1.0
[M+H]+222.3177817
predicted
DarkChem Lite v0.1.0
[M+Na]+223.0501817
predicted
DarkChem Lite v0.1.0

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:19965576, PubMed:20702771, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:21490593, PubMed:21576599, PubMed:2732228). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:12865317, PubMed:14559847). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:15373842, PubMed:15764715, PubMed:22773874, PubMed:2732228). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:15373842, PubMed:15764715, PubMed:2732228). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850). Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:29461981)
Specific Function
1,8-cineole 2-exo-monooxygenase activity
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
A cytochrome P450 monooxygenase involved in the metabolism of steroid hormones and vitamins (PubMed:10681376, PubMed:11093772, PubMed:12865317, PubMed:2732228). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:10681376, PubMed:11093772, PubMed:12865317, PubMed:2732228). Exhibits high catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes 6beta-hydroxylation of the steroid hormones testosterone, progesterone, and androstenedione (PubMed:2732228). Catalyzes the oxidative conversion of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Also involved in the oxidative metabolism of xenobiotics, including calcium channel blocking drug nifedipine and immunosuppressive drug cyclosporine (PubMed:2732228)
Specific Function
aromatase activity
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]

Drug created at September 01, 2018 21:25 / Updated at October 14, 2024 10:06